Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020.

Poly ADP-ribose polymerase (PARP) inhibitors have transformed the treatment landscape of high-grade ovarian cancer.[1][1] The presence of homologous recombination deficiencies and particularly alterations in the BRCA genes are well described biomarkers of response.[2][2] Until the American Society